New drug cocktail aims to beat back aggressive leukemia in older adults

NCT ID NCT05260528

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a newer chemotherapy drug called CPX-351 works better than standard chemo for adults aged 50 and older with a hard-to-treat form of acute myeloid leukemia (AML). About 248 people will be randomly assigned to receive either CPX-351 or standard chemo. The main goal is to see if CPX-351 leads to deeper remissions with less cancer left behind in the bone marrow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CPX-351 (a combination of two chemotherapy drugs, daunorubicin and cytarabine, in a liposomal formulation)
What this could lead to: If CPX-351 works better than standard chemo, it could become a new first-line treatment for older adults with harder-to-treat AML, improving remission rates and reducing relapse.
What could go wrong: This is a phase 2 trial, so results are still early. CPX-351 may not prove superior to standard chemo, and both treatments have serious side effects like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

CH Avignon
RECRUITING

Avignon, France
CH de Roubaix
RECRUITING

Roubaix, France
CHR Metz-Thionville Site Mercy
RECRUITING

Metz, France
CHR Orléans
RECRUITING

Orléans, France
CHRU Jean Minjoz
RECRUITING

Besançon, France
CHU Amiens Picardie site Sud
RECRUITING

Amiens, France
CHU Estaing
RECRUITING

Clermont-Ferrand, France
CHU Henri Mondor
RECRUITING

Créteil, France
CHU d'Angers
NOT_YET_RECRUITING

Angers, France
CHU de Bordeaux
RECRUITING

Pessac, France
CHU de Limoges
RECRUITING

Limoges, France
CHU de Nantes
NOT_YET_RECRUITING

Nantes, France
CHU de Nice
RECRUITING

Nice, France
CHU de Saint Etienne
RECRUITING

Saint-Priest-en-Jarez, France
CHU de Toulouse
RECRUITING

Toulouse, France
Centre Antoine Lacassagne
NOT_YET_RECRUITING

Nice, France
Centre Henri Becquerel
RECRUITING

Rouen, France
Centre Hospitalier Sud Francilien (CHSF)
RECRUITING

Corbeil-Essonnes, France
Centre Hospitalier de Béziers
RECRUITING

Béziers, France
Centre Hospitalier de Versailles, Site André Mignot
RECRUITING

Le Chesnay, France
Groupe hospitalier de la région de Mulhouse et Sud-Alsace, Hôpital Emile Muller
RECRUITING

Mulhouse, France
Hopital Bretonneau
RECRUITING

Tours, France
Hopital Lyon Sud
RECRUITING

Pierre-Bénite, France
Hopital Necker
RECRUITING

Paris, France
Hoptial de la Conception APHM
RECRUITING

Marseille, France
Hôpital Avicenne APHP
RECRUITING

Bobigny, France
Hôpital Claude HURIEZ, CHU Lille
RECRUITING

Lille, France
Hôpital Saint-Antoine
RECRUITING

Paris, France
Hôpital Saint-Louis
RECRUITING

Paris, France
Hôpital d'Instruction des Armée (HIA)
RECRUITING

Clamart, France
Hôpital de la Pitié Salpêtrière
RECRUITING

Paris, France
Institut Gustave Roussy
RECRUITING

Villejuif, France
Institut Paoli Calmettes
RECRUITING

Marseille, France
Institut d'hématologie de Basse Normandie (IHBN)
RECRUITING

Caen, France
Institut de cancérologie du Gard
RECRUITING

Nîmes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.